These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 32597258)
21. Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. Iacovelli R; Sternberg CN; Porta C; Verzoni E; de Braud F; Escudier B; Procopio G Curr Drug Targets; 2015; 16(2):164-70. PubMed ID: 25410406 [TBL] [Abstract][Full Text] [Related]
22. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs. Thanigaimani S; Kichenadasse G; Mangoni AA Curr Vasc Pharmacol; 2011 May; 9(3):358-80. PubMed ID: 20807189 [TBL] [Abstract][Full Text] [Related]
23. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy. Tarallo V; De Falco S Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669 [TBL] [Abstract][Full Text] [Related]
24. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205 [TBL] [Abstract][Full Text] [Related]
25. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Bronte G; Bronte E; Novo G; Pernice G; Lo Vullo F; Musso E; Bronte F; Gulotta E; Rizzo S; Rolfo C; Silvestris N; Bazan V; Novo S; Russo A Expert Opin Drug Saf; 2015 Feb; 14(2):253-67. PubMed ID: 25494575 [TBL] [Abstract][Full Text] [Related]
26. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Girardi F; Franceschi E; Brandes AA Oncologist; 2010; 15(7):683-94. PubMed ID: 20547589 [TBL] [Abstract][Full Text] [Related]
27. Current status of angiogenesis inhibitors combined with radiation therapy. Nieder C; Wiedenmann N; Andratschke N; Molls M Cancer Treat Rev; 2006 Aug; 32(5):348-64. PubMed ID: 16713103 [TBL] [Abstract][Full Text] [Related]
30. Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery. Chimote G; Sreenivasan J; Pawar N; Subramanian J; Sivaramakrishnan H; Sharma S Drug Des Devel Ther; 2014; 8():1107-23. PubMed ID: 25170251 [TBL] [Abstract][Full Text] [Related]
31. Anti-VEGF Anticancer Drugs: Mind the Hypertension. Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049 [TBL] [Abstract][Full Text] [Related]
32. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Kiselyov A; Balakin KV; Tkachenko SE Expert Opin Investig Drugs; 2007 Jan; 16(1):83-107. PubMed ID: 17155856 [TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249 [TBL] [Abstract][Full Text] [Related]
34. [Anti-angiogenesis targeting drugs: a review]. Jia K; Li J Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135 [TBL] [Abstract][Full Text] [Related]
35. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). Peng FW; Liu DK; Zhang QW; Xu YG; Shi L Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580 [TBL] [Abstract][Full Text] [Related]
36. Cardiovascular toxicity of new agents. Maitland ML Clin Adv Hematol Oncol; 2008 Sep; 6(9):657-9. PubMed ID: 18827788 [No Abstract] [Full Text] [Related]
37. Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect. Kras P; Talkowski K; Grabarek BO; Skalska-Dziobek N; Boroń D; Oplawski M Curr Pharm Biotechnol; 2021; 22(5):697-705. PubMed ID: 32648839 [TBL] [Abstract][Full Text] [Related]
38. Molecular design and clinical development of VEGFR kinase inhibitors. Zhong H; Bowen JP Curr Top Med Chem; 2007; 7(14):1379-93. PubMed ID: 17692027 [TBL] [Abstract][Full Text] [Related]
40. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials. Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]